On Tuesday, Takeda Pharmaceutical Co ADR (NYSE: TAK) opened lower -2.04% from the last session, before settling in for the closing price of $13.74. Price fluctuations for TAK have ranged from $12.57 to $15.08 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 11.56%. Company’s average yearly earnings per share was noted -10.87% at the time writing. With a float of $3.17 billion, this company’s outstanding shares have now reached $3.17 billion.
Considering the fact that the conglomerate employs 49281 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 62.47%, operating margin of 14.14%, and the pretax margin is 5.85%.
Takeda Pharmaceutical Co ADR (TAK) Insider Activity
A key investor’s attitude towards the stock of the Drug Manufacturers – Specialty & Generic industry is another important factor to consider. The insider ownership of Takeda Pharmaceutical Co ADR is 0.02%, while institutional ownership is 5.17%. The most recent insider transaction that took place on Aug 23 ’24, was worth 284,951. Before that another transaction happened on Jan 24 ’24, when Company’s 10% Owner sold 3,703,703 for $8.10, making the entire transaction worth $29,999,994. This insider now owns 3,755,583 shares in total.
Takeda Pharmaceutical Co ADR (TAK) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -10.87% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 35.03% during the next five years compared to -12.87% drop over the previous five years of trading.
Takeda Pharmaceutical Co ADR (NYSE: TAK) Trading Performance Indicators
Check out the current performance indicators for Takeda Pharmaceutical Co ADR (TAK). In the past quarter, the stock posted a quick ratio of 0.77. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.41. Likewise, its price to free cash flow for the trailing twelve months is 10.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.60, a number that is poised to hit 0.09 in the next quarter and is forecasted to reach 0.44 in one year’s time.
Technical Analysis of Takeda Pharmaceutical Co ADR (TAK)
Compared to the last year’s volume of 1.84 million, its volume of 1.48 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 58.61%. Additionally, its Average True Range was 0.18.
During the past 100 days, Takeda Pharmaceutical Co ADR’s (TAK) raw stochastic average was set at 13.37%, which indicates a significant decrease from 30.12% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 18.94% in the past 14 days, which was higher than the 17.78% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.87, while its 200-day Moving Average is $13.84. Nevertheless, the first resistance level for the watch stands at $13.57 in the near term. At $13.69, the stock is likely to face the second major resistance level. The third major resistance level sits at $13.74. If the price goes on to break the first support level at $13.40, it is likely to go to the next support level at $13.35. Should the price break the second support level, the third support level stands at $13.23.
Takeda Pharmaceutical Co ADR (NYSE: TAK) Key Stats
There are currently 3,181,875K shares outstanding in the company with a market cap of 42.67 billion. Presently, the company’s annual sales total 29,420 M according to its annual income of 994,060 K. Last quarter, the company’s sales amounted to 7,904 M and its income totaled 618,620 K.
